Clinical trial
Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients…
NCT00306150 · Bayer, Industry · Terminated
Key facts
| NCT number | NCT00306150 |
|---|---|
| Title | Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy |
| Official title | A Multi-center, Randomized, Double Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients With Bladder Cancer Undergoing Radical or Total Cystectomy. |
| Lead sponsor | Bayer, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Blood Loss, Surgical, Postoperative Hemorrhage |
| Intervention type | Drug |
| Interventions | Trasylol (Aprotinin, BAYA0128), Placebo |
| Enrollment | 57 |
| Start date | Dec 1, 2005 |
| Completion | Mar 1, 2007 |
| First posted | Mar 23, 2006 |
| Last update posted | Dec 17, 2014 |
| Countries | Belgium, France, Germany, Netherlands, Sweden, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: